Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AusperBio Updates Clinical Progress of Antisense Oligonucleotide Therapy for HBV

publication date: Feb 15, 2024

AusperBio, a Hangzhou-San Francisco biopharma, reported its lead candidate, AHB-137, an unconjugated antisense oligonucleotide (ASO) that targets all HBV RNA, is advancing through clinical trials in China and the US. The company believes AHB-137 will prove to be a functional cure for chronic hepatitis B. The candidate is a product of AusperBio’s proprietary Med-OligoTM ASO platform, which the company expects will produce more effective therapies than available ASO offerings. Currently, two Phase Ia/Ib clinical trials, one in China and the other in the US/New Zealand, have dosed 122 participants, including 30 CHB patients. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here